Correction to: Scientific reports https://doi.org/10.1038/s41598-020-60409-4, published online 26 February 2020
Noor Diab was omitted from the author list in the original version of this Article.
The Author Contributions section now reads:
S.M., A.S., M.L.-A., A.V., and K.B.C. designed the experiments. S.M., A.S., S.G., M.H., P.T.A., S.C., E.P., K.R., N.D., and A.Y. performed experiments. J.L. and W.Z. provided cisplatin-resistant cell lines IGROV-1 CR and SKOV3 CR. S.M., A.S., S.G., A.V., and K.B.C. wrote, edited, and revised the manuscript.
The original Article and accompanying Supplementary Information file has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Moufarrij, S., Srivastava, A., Gomez, S. et al. Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci Rep 11, 24423 (2021). https://doi.org/10.1038/s41598-021-04066-1
Published:
DOI: https://doi.org/10.1038/s41598-021-04066-1
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
